Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Inclusion Criteria: * Patients with peripheral T-cell lymphoma confirmed by primary pathology; * Age 18-70 years; * ECOG performance status ≤ 2; * Adequate bone marrow hematopoietic function: WBC \> 3.5 × 10\*9/L，ANC\>1.5 × 10\*9/L，HGB\>90g/L，PLT\>80 × 10\*9/L; * Adequate organ function: cardiac function grade 0-2 (NYHA); SpO2 \> 88% (natural condition); ALT\<3UNL，TBil\<2ULN; SCr\>60ml/min/m2; * Patients have signed the Informed Consent Form Exclusion Criteria: * ALK positive anaplastic T-cell lymphoma; * NK / T cell lymphoma, nasal type; * Uncontrolled active infection; * Acute myocardial infarction or unstable angina pectoris within 6 months; uncontrolled hypertension, symptomatic arrhythmia, etc; * Subjects who are known or suspected to be unable to comply with the study protocol; * Pregnant or lactating women